CN3924655
Active
Amendment A1
Imported Plasma and Recombinant Products
$271.3M
Contract Value
Contract Details
- Contract ID
- CN3924655
- Status
- active
- Financial Year
- FY27
- Category
- Drugs and Pharmaceutical(UNSPSC: 51000000)
Key Dates
- Publish Date
- 3 July 2026
- Signed Date
- 2 Nov 2022
- Start Date
- 30 Sept 2022
- End Date
- 29 June 2027
- Duration
- 4 years, 10 months
Procurement Information
- Procurement Method
- Limited tender
- Exemption Code
- ER
- Exemption Reason
- 10.3.d.ii. Supply by particular business: with no reasonable alternative or substitute: to protect exclusive rights or proprietary information.
Contract History
This contract has been amended 1 time. Currently showing amendment A1.
Original Contract
Published 2 Nov 2022 · 30 Sept 2022 to 29 June 2027
$246.6M
Amendment A1
Current
Published 3 July 2026 · 30 Sept 2022 to 29 June 2027
$271.3M
+$24.7M
Supplier
CSL BEHRING (AUSTRALIA) PTY LTD
- ABN
- 48 160 734 761
- Entity Type
- Australian Private Company
- Location
- VIC
Agency
More from CSL BEHRING (AUSTRALIA) PTY LTD
National Fractionation Agreement
$3.4BNational Blood Authority
National Supply arrangement for imported immunoglobulin products
$1.9BNational Blood Authority
Procurement of Imported Plasma and Recombinant Products (IPRP) - Idelvion
$73.6MNational Blood Authority
Imported Plasma and Recombinant Products (Factor XI Concentrate)
$8.3MNational Blood Authority
Pharmaceutical Products
$23KDepartment of Defence